These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 31230047)

  • 21. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Advani RH; Buggy JJ; Sharman JP; Smith SM; Boyd TE; Grant B; Kolibaba KS; Furman RR; Rodriguez S; Chang BY; Sukbuntherng J; Izumi R; Hamdy A; Hedrick E; Fowler NH
    J Clin Oncol; 2013 Jan; 31(1):88-94. PubMed ID: 23045577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.
    Antonia SJ; Balmanoukian A; Brahmer J; Ou SI; Hellmann MD; Kim SW; Ahn MJ; Kim DW; Gutierrez M; Liu SV; Schöffski P; Jäger D; Jamal R; Jerusalem G; Lutzky J; Nemunaitis J; Calabrò L; Weiss J; Gadgeel S; Bhosle J; Ascierto PA; Rebelatto MC; Narwal R; Liang M; Xiao F; Antal J; Abdullah S; Angra N; Gupta AK; Khleif SN; Segal NH
    J Thorac Oncol; 2019 Oct; 14(10):1794-1806. PubMed ID: 31228626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Ibrutinib: A new drug of B-cell malignancies].
    Thieblemont C
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies.
    Tobinai K; Ogura M; Ishizawa K; Suzuki T; Munakata W; Uchida T; Aoki T; Morishita T; Ushijima Y; Takahara S
    Int J Hematol; 2016 Jan; 103(1):86-94. PubMed ID: 26588924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study.
    Algazi A; Papadopoulos KP; Tsai F; Hansen AR; Angra N; Das M; Sheth S; Siu LL
    ESMO Open; 2024 Aug; 9(8):103646. PubMed ID: 39043009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
    O'Brien S; Furman RR; Coutre SE; Sharman JP; Burger JA; Blum KA; Grant B; Richards DA; Coleman M; Wierda WG; Jones JA; Zhao W; Heerema NA; Johnson AJ; Izumi R; Hamdy A; Chang BY; Graef T; Clow F; Buggy JJ; James DF; Byrd JC
    Lancet Oncol; 2014 Jan; 15(1):48-58. PubMed ID: 24332241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
    Bartlett NL; Costello BA; LaPlant BR; Ansell SM; Kuruvilla JG; Reeder CB; Thye LS; Anderson DM; Krysiak K; Ramirez C; Qi J; Siegel BA; Griffith M; Griffith OL; Gomez F; Fehniger TA
    Blood; 2018 Jan; 131(2):182-190. PubMed ID: 29074501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
    Planchard D; Yokoi T; McCleod MJ; Fischer JR; Kim YC; Ballas M; Shi K; Soria JC
    Clin Lung Cancer; 2016 May; 17(3):232-236.e1. PubMed ID: 27265743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
    Cheah CY; Chihara D; Romaguera JE; Fowler NH; Seymour JF; Hagemeister FB; Champlin RE; Wang ML
    Ann Oncol; 2015 Jun; 26(6):1175-1179. PubMed ID: 25712454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
    Gopal AK; Schuster SJ; Fowler NH; Trotman J; Hess G; Hou JZ; Yacoub A; Lill M; Martin P; Vitolo U; Spencer A; Radford J; Jurczak W; Morton J; Caballero D; Deshpande S; Gartenberg GJ; Wang SS; Damle RN; Schaffer M; Balasubramanian S; Vermeulen J; Cheson BD; Salles G
    J Clin Oncol; 2018 Aug; 36(23):2405-2412. PubMed ID: 29851546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
    Davids MS; Brown JR
    Future Oncol; 2014 May; 10(6):957-67. PubMed ID: 24941982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
    Garon EB; Spira AI; Goldberg SB; Chaft JE; Papadimitrakopoulou V; Cascone T; Antonia SJ; Brahmer JR; Camidge DR; Powderly JD; Wozniak AJ; Felip E; Wu S; Ascierto ML; Elgeioushi N; Awad MM
    J Thorac Oncol; 2023 Aug; 18(8):1094-1102. PubMed ID: 37146752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ibrutinib for treatment of chronic lymphocytic leukemia.
    Vela CM; McBride A; Jaglowski SM; Andritsos LA
    Am J Health Syst Pharm; 2016 Mar; 73(6):367-75. PubMed ID: 26953281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma.
    Grommes C; Nandakumar S; Schaff LR; Gavrilovic I; Kaley TJ; Nolan CP; Stone J; Thomas AA; Tang SS; Wolfe J; Bozza A; Wongchai V; Hyde A; Barrett E; Lynch EA; Madzsar JT; Lin A; Piotrowski AF; Pentsova E; Francis JH; Hatzoglou V; Schultz N; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
    Clin Cancer Res; 2024 Sep; 30(18):4005-4015. PubMed ID: 38995739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
    Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Shibayama H; Choi I; Hatake K; Uchida T; Nishikori M; Kinoshita T; Matsuno Y; Nishikawa T; Takahara S; Tobinai K
    Cancer Sci; 2016 Dec; 107(12):1785-1790. PubMed ID: 27616553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
    Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
    Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.
    Tillman BF; Pauff JM; Satyanarayana G; Talbott M; Warner JL
    Eur J Haematol; 2018 Apr; 100(4):325-334. PubMed ID: 29285806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 39. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
    Chari A; Cornell RF; Gasparetto C; Karanes C; Matous JV; Niesvizky R; Lunning M; Usmani SZ; Anderson LD; Chhabra S; Girnius S; Shustik C; Stuart R; Lee Y; Salman Z; Liu E; Valent J
    Hematol Oncol; 2020 Aug; 38(3):353-362. PubMed ID: 32053229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
    Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
    Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.